MedTrace Logo

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

NCT05417971 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-04-16

No results posted yet for this study

Summary

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.

Conditions

  • Hematologic Malignancy

Interventions

OTHER

Fludarabine

Reduced-intensity fludarabine with intermediate-dose TBI

Sponsors & Collaborators

  • Northside Hospital, Inc.

    lead OTHER

Principal Investigators

  • Scott Solomon, MD · BMTGA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417971 on ClinicalTrials.gov